Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$290.08M$290.08M+34.3% vs Q3 2023 Net Income$137.01M$137.01M+67.4% vs Q3 2023 EPS Diluted$1.05$1.05+72.1% vs Q3 2023 Operating Income$163,197,000+84.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$113,859,000−12.1% Margins · derivedOperating margin56.3%+15.4 pt vs Q3 2023
Net margin47.2%+9.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Oct 31, 2024 · 31 d after period end